In 2023, diabetes medicine sales in Italy were at 1.45 billion USD. Forecasts predict a steady growth in sales from 2024 to 2028, with figures reaching 1.59 billion USD by the latter year. The year-on-year percentage increase hovers around 2% annually, indicating incremental growth. The compound annual growth rate (CAGR) over this five-year period is estimated at approximately 1.8%, reflecting a stable upward trend.

Future trends to watch for include:

Developments in new diabetes treatments that may impact sales.
Changing healthcare policies in Italy that could affect medicine availability and pricing.
Increased emphasis on preventive care potentially altering traditional demand for diabetes medication.